effect of Agomelatin on the migraine

The effectiveness of agomelatine on the severity and numbers of migraine attacks in patients with migraine

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20230303057599N1

Enrollment

Registered

2023-05-24

Start date

2021-09-06

Completion date

Unknown

Last updated

2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine. Migraine without aura [common migraine]

Interventions

Intervention 1: Intervention group: This group receives agomelatine 25 mg daily in tablet form for three months. Intervention 2: Control group: This group receives vitamin B1 tablets with the same sha

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Migraine without aura without the use of preventive medicine

Exclusion criteria

Exclusion criteria: Pregnant woman those taking certain medications

Design outcomes

Primary

Measure	Time frame
Severity and number of headache attacks. Timepoint: Three months after the intervention. Method of measurement: Checklist and interview.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShafiee Sabet Mahdi

Tehran University of Medical Sciences

mshafiees@sina.tums.ac.ir+98 21 5575 1333

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 9, 2026